As described below, the present invention features compositions and methods for treating brain and/or behavioral health disorders and their associated symptoms.

As described below, the present invention features compositions and methods for treating brain and/or behavioral health disorders and their associated symptoms.

As described below, the present invention features compositions and methods for treating brain and/or behavioral health disorders and their associated symptoms.

Calcium hydroxide nanoparticles (Ca(OH).sub.2NPs) synthesized using carob pulp extract may be hexagonal nanoparticles with a diameter ranging from about 31.22 nm to about 81.22 nm. The Ca(OH).sub.2NPs may be synthesized by heating ethylene glycol, adding calcium hydroxide to the ethylene glycol to provide a first mixture, heating the first mixture, adding a carob pulp aqueous extract to the first mixture to form a second mixture, heating the second mixture, adding sodium hydroxide (NaOH) to the second mixture to form a third mixture, heating the third mixture, resting the third mixture at room temperature after heating, centrifuging the third mixture, collecting a colloid sediment, extracting any unwanted contaminants from the colloid sediment, and drying the colloid sediment to obtain Ca(OH).sub.2NPs.

Calcium hydroxide nanoparticles (Ca(OH).sub.2NPs) synthesized using carob pulp extract may be hexagonal nanoparticles with a diameter ranging from about 31.22 nm to about 81.22 nm. The Ca(OH).sub.2NPs may be synthesized by heating ethylene glycol, adding calcium hydroxide to the ethylene glycol to provide a first mixture, heating the first mixture, adding a carob pulp aqueous extract to the first mixture to form a second mixture, heating the second mixture, adding sodium hydroxide (NaOH) to the second mixture to form a third mixture, heating the third mixture, resting the third mixture at room temperature after heating, centrifuging the third mixture, collecting a colloid sediment, extracting any unwanted contaminants from the colloid sediment, and drying the colloid sediment to obtain Ca(OH).sub.2NPs.

Use of a solid calcium compound in the fabrication of a hemostatic agent for reducing bleeding from a surgical site during and/or after a surgical treatment in a patient is provided, wherein the solid calcium compound is selected from the group consisting of calcium phosphate, calcium sulfate, calcium carbonate, calcium oxide, calcium hydroxide, hydroxyapatite, and a combination thereof.

An aspect provides a pharmaceutical composite formulation containing: a first layer comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, a disintegrant, and a binder; and a second layer comprising, as an active ingredient, an antacid selected from magnesium hydroxide, magnesium oxide, or a mixture thereof.

An aspect provides a pharmaceutical composite formulation containing: a first layer comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, a disintegrant, and a binder; and a second layer comprising, as an active ingredient, an antacid selected from magnesium hydroxide, magnesium oxide, or a mixture thereof.

The present disclosure provides, inter alia, a method for making a solid fermented product useful for animal feed comprising the steps of adding a source of calcium to a fermented liquid comprising ammonium lactate.

The present disclosure provides, inter alia, a method for making a solid fermented product useful for animal feed comprising the steps of adding a source of calcium to a fermented liquid comprising ammonium lactate.